Yifan Dai

Yifan Dai

Auto-generated profile, based on publicly available information

Yifan Dai

Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYining Zhu
Yining Zhu
ZYZhi-Cheng Yao
Zhi-Cheng Yao
SLShuyi Li
Shuyi Li
JMJingyao Ma
Jingyao Ma
CWChristine Wei
Christine Wei
HMHai-Quan Mao
Hai-Quan Mao
Hydrogel materials have emerged as versatile platforms for various biomedical applications. Notably, the engineered nanofiber-hydrogel composite (NHC) has proven effective in mimicking the soft tissue extracellular matrix, facilitating substantial recruitment of host immune cells and the formation of a local immunostimulatory microenvironment. Leveraging this feature, here we report an mRNA lipid nanoparticle (LNP)-incorporated NHC microgel matrix, termed LiNx, by incorporating LNPs loaded with mRNA encoding tumour antigens. Harnessing the high transfection efficiency of LNPs in antigen-presenting cells, LiNx demonstrates substantial levels of immune cell recruitment, antigen expression and presentation, and cellular interaction. These attributes collectively create an immunostimulating microenvironment and yield a potent immune response with a single dose at a level comparable to the conventional three-dose LNP immunization protocol. Further investigation reveals that the LiNx generates not only high levels of Th1 and Th2 responses, but also a distinct Type 17 T helper cell response critical for bolstering antitumour efficacy. Our findings elucidate the mechanism underlying LiNx’s role in potentiating antigen-specific immune responses, presenting a strategy for cancer immunotherapy.

26 April 2025 in Bioinformatics
Verified
Journal Article
Open access
YDYifan Dai
Yifan Dai
DWDi Wu
Di Wu
ICIan M Carroll
Ian M Carroll
FZFei Zou
Fei Zou
BZBaiming Zou
Baiming Zou
Motivation: Omics features, often measured by high-throughput technologies, combined with clinical features, significantly impact the understanding of many complex human diseases. Integrating key omics biomarkers with clinical risk factors is essential for elucidating disease mechanisms, advancing early diagnosis, and enhancing precision medicine. However, the high dimensionality and intricate associations between disease outcomes and omics profiles present substantial analytical challenges. Results: We propose a high-dimensional feature importance test (HiFIT) framework to address these challenges. Specifically, we develop an ensemble data-driven biomarker identification tool, Hybrid Feature Screening (HFS), to construct a candidate feature set for downstream machine learning models. The pre-screened candidate features from HFS are further refined using a computationally efficient permutation-based feature importance test employing machine learning methods to flexibly model the potential complex associations between disease outcomes and molecular biomarkers. Through extensive numerical simulation studies and practical applications to microbiome-associated weight changes following bariatric surgery, as well as the examination of gene-expression-associated kidney pan-cancer survival data, we demonstrate HiFIT’s superior performance in both outcome prediction and feature importance identification. Availability and implementation: An R package implementing the HiFIT algorithm is available on GitHub (https://github.com/BZou-lab/HiFIT).

3 July 2025 in Biometrics
Verified
Journal Article
Closed access
YDYifan Dai
Yifan Dai
DWDi Wu
Di Wu
YLYufeng Liu
Yufeng Liu
Clustering is widely used in biomedical research for meaningful subgroup identification. However, most existing clustering algorithms do not account for the statistical uncertainty of the resulting clusters and consequently may generate spurious clusters due to natural sampling variation. To address this problem, the Statistical Significance of Clustering (SigClust) method was developed to evaluate the significance of clusters in high-dimensional data. While SigClust has been successful in assessing clustering significance for continuous data, it is not specifically designed for discrete data, such as count data in genomics. Moreover, SigClust and its variations can suffer from reduced statistical power when applied to non-Gaussian high-dimensional data. To overcome these limitations, we propose SigClust-DEV, a method designed to evaluate the significance of clusters in count data. Through extensive simulations, we compare SigClust-DEV against other existing SigClust approaches across various count distributions and demonstrate its superior performance. Furthermore, we apply our proposed SigClust-DEV to Hydra single-cell RNA sequencing (scRNA) data and electronic health records (EHRs) of cancer patients to identify meaningful latent cell types and patient subgroups, respectively.

28 July 2026
Verified
Conference Paper
Closed access
YDYifan Dai
Yifan Dai
Unbalanced classification poses a significant challenge in real-world applications such as medical diagnosis and fraud detection, where class label distributions are highly skewed. Standard classification methods on such data can lead to poor classification results, sacrificing classification accuracy on minority classes. Standard classification methods often yield suboptimal results by sacrificing minority class accuracy to maximize overall performance. Common techniques to address unbalanced classification typically involve weighting adjustments of points for different classes or resampling strategies, including oversampling of minority classes and undersampling of majority classes. While these balancing techniques are effective in improving classification accuracy, they often introduce biases that compromise posterior class probability estimation and model calibration. This paper highlights the trade-offs associated with balancing techniques when applied without appropriate adjustments. We systematically investigate the distortions in probability estimation caused by these unbalanced classification techniques and propose a robust framework to correct these biases through probability adjustment. We further investigate high-dimensional unbalanced data, examining both the distortion induced by balancing techniques and the shrinkage effect of regularization on probability estimation. Finally, our method is evaluated through simulations and real data analysis. Finally, our method is evaluated through simulations and real data analysis, covering a range of balancing strategies including class weighting, random resampling, and generative models. Results demonstrate that our proposed framework significantly mitigates probability estimation bias while preserving classification power when applying traditional balancing techniques, ensuring reliable posterior estimates.

7 August 2026 in Communications Medicine
Verified
Journal Article
Open access
PDF file
YDYifan Dai
Yifan Dai
YQYixiang Qu
Yixiang Qu
KXKai Xia
Kai Xia
FZFei Zou
Fei Zou
BZBaiming Zou
Baiming Zou
Background The integration of high-dimensional and multi-modal biomarker data remains a central challenge in precision medicine, hindered by noise, weak individual signals, and heterogeneous data structures. Methods We propose AdaMixNet, an adaptive mixed-effects deep learning framework that unifies nonlinear fixed-effects modeling with kernel-based random-effects estimation to robustly and accurately predict complex disease outcomes. By leveraging feature screening to distinguish sparse, high-impact biomarkers from dense, low-signal features, AdaMixNet captures both strong and subtle biological effects across diverse data modalities. Results Through comprehensive simulations and applications to two large-scale real cohorts, i.e., METABRIC (breast cancer) and ADNI (Alzheimer’s disease), AdaMixNet shows robust overall performance, often outperforming strong machine-learning and statistical baselines in simulation and achieving competitive or best results for several real-data outcomes while maintaining good performance across sample sizes from 1000 to 20,000. Conclusions AdaMixNet offers a generalizable and interpretable framework for integrating high-dimensional and multi-modal omics profiles with low-dimensional clinical data, accelerating the translation of molecular insights into clinical applications.

16 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
PTPradham Tanikella
Pradham Tanikella
WNWilliam Nenad
William Nenad
CCChristophe Courtine
Christophe Courtine
YDYifan Dai
Yifan Dai
QDQingying Deng
Qingying Deng
DWDi Wu
Di Wu
Background/Objectives: Head and neck cancer (HNC) represents the seventh most common cancer diagnosis globally, yet current treatments, including surgery, radiation, and immunotherapy, have shown limited improvement in outcomes. Drug repurposing offers a cost-effective strategy to identify new therapeutic options by leveraging existing medications with known safety profiles. Within this study we developed the GARD pipeline ( G enomic A lteration-based R epurposing for D rugs), designed to uncover repurposing candidates for HNC using genomic and network-based approaches. Methods: GARD integrates multi-omics data from The Cancer Genome Atlas (TCGA), including copy number variation (CNV) and somatic mutations (SOM). The cohort was stratified by human papillomavirus (HPV) status. Risk-associated genes were identified and then expanded via high-confidence protein–protein interaction (PPI) networks. Top candidate genes were filtered through comprehensive analysis of publicly available literature data in PubMed using LLM to validate the relationship between the identified genes and HNC. The validated top risk genes and their network-expanded neighbors were mapped against DrugBank, and through statistical significance testing, established significant drug-gene associations. Results: Significant genes associated with HNC, inferred by genomics alteration, were identified across HPV-positive and HPV-negative subgroups, such as PIK3CA, SOX2, TP53, EIF4G1, TLR7, CLDN1, PRKCI, and EPHA2. Further expansion through the PPI network identified other targetable genes such as EGFR, ERBB2, and the FGFRs. Literature based validation efforts ensured provided confidence in the gene-disease association. Drug-gene mapping revealed candidates spanning already in clinical trials for HNC (e.g. Afatinib, Cabozantinib, Dasatinib, Brigatinib, Lenvatinib, Capivasertib, Erdafitinib) and emerging or repurposing candidates (Amuvatinib, XL765 (Voxtalisib), Golotimod, Artenimol, Quercetin, and Acetylsalicylic Acid), offering opportunities for precision repurposing. Conclusions: The GARD pipeline demonstrates a genomics-driven, network-informed framework for systematic drug repurposing in HNC. HPV stratification enhances precision, literature-based validation strengthens confidence, and integrated drug mapping enables refinement of existing therapies and discovery of novel candidates for personalized treatment strategies. Code Availability: The full implementation of the GARD pipeline, including preprocessing scripts, statistical analysis modules, and visualization tools, is publicly available on GitHub at: https://github.com/pvtanike/Genomic-Landscape-Based-Drug-Repurposing.git Simple Summary: Head and neck cancer (HNC) is among the most prevalent and challenging cancers world-wide. Developing new drugs is expensive and time-consuming, so this study explored a faster, cost-effective approach utilizing existing medications with established safety profiles: drug repurposing. We developed the GARD pipeline ( G enomic A lteration-based R epurposing for D rugs), which utilizes large-scale genomic data from The Cancer Genome Atlas (TCGA) to identify key genomics changes in HNC. These genes are expanded through protein–protein interaction networks to capture related pathways and then validated using evidence from thousands of PubMed articles extracted by large language model (LLM) tools. Finally, validated genes are matched with drugs using the DrugBank database. This approach uncovered both known cancer drugs and promising new candidates. These included targeted therapies such as Fostamatinib, Nintedanib, Brigatinib, Regorafenib, and Lenvatinib, as well as emerging compounds like Artenimol, Quercetin, and Acetylsalicylic Acid (Aspirin). Through a combination of genomic analysis, network expansion, and literature validation, the GARD pipeline offers a powerful way to accelerate personalized cancer treatments while reducing cost and development time.